Roche's Genentech Gets FDA sBLA Acceptance for Lunsumio VELO And Polivy Combination In Relapsed or Refractory Large B-Cell Lymphoma
هوفمان-لا روش
هوفمان-لا روش ADR
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death –
– People with relapsed or refractory LBCL represent one of the highest unmet need populations in lymphoma and require timely access to effective therapies –
– If approved, this outpatient-ready regimen could enable access to care in the community setting, where most U.S. patients receive treatment –